Article
type: Class

Document
type: Class

Anualidad
type: Class

Academic Article
type: Class

Information Content Entity
type: Class

Continuant
type: Class

Entity
type: Class

Generically Dependent Continuant
type: Class

2016
type: Class

RDF description of STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer - http://research.umh.es/vivo/pub/articulo/169509
type: Document
rights: termsOfUse
date: 2026-08-20T08:07:44
publisher: STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer

STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer
type: Generically Dependent Continuant
page start: 1
type: Anualidad
page end: 6
type: Information Content Entity
related by: Autor:3806-Artículo:169509
has publication venue: CELL CYCLE
related by: AutorExt:273046_2016-Artículo:169509
most specific type: Academic Article
type: Document
type: Continuant
related by: AutorExt:273044_2016-Artículo:169509
date time value: 169509 pubdate
related by: Autor:129836-Artículo:169509
type: 2016
type: Thing
type: Academic Article
ARG_2000028: 169509 vcard
type: Entity
most specific type: 2016
type: Article
related by: AutorExt:273045_2016-Artículo:169509

Autor:3806-Artículo:169509
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer

CELL CYCLE
type: Collection
type: Information Content Entity
type: Generically Dependent Continuant
type: Continuant
type: Journal
type: Entity
type: Periodical
publication venue for: STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer
type: Thing

AutorExt:273046_2016-Artículo:169509
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer

AutorExt:273044_2016-Artículo:169509
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer

Autor:129836-Artículo:169509
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer

AutorExt:273045_2016-Artículo:169509
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer